Post Hoc Analysis Shows Imetelstat Drives Benefit in RS-Negative, Lower-Risk MDS
Bexobrutideg Is Tolerable and Yields High Response Rates in Relapsed/Refractory Waldenström Macroglobulinemia
Axi-Cel, Liso-Cel, and Tisa-Cel Show Comparable Real-World Survival Outcomes in DLBCL
Pirtobrutinib Improves Patient-Reported Outcomes in Relapsed/Refractory CLL/SLL
